Kimberly J Van Zee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2179325/publications.pdf Version: 2024-02-01

		23567	31849
169	11,357	58	101
papers	citations	h-index	g-index
171	171	171	8380
	1/1	1/1	0302
all docs	docs citations	times ranked	citing authors

KIMBEDLY I VAN ZEE

#	Article	IF	CITATIONS
1	Routine Opioid Prescriptions Are Not Necessary After Breast Excisional Biopsy or Lumpectomy Procedures. Annals of Surgical Oncology, 2021, 28, 303-309.	1.5	8
2	Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. Annals of Surgical Oncology, 2021, 28, 5134-5140.	1.5	11
3	Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. Breast Cancer Research and Treatment, 2021, 186, 617-624.	2.5	8
4	Reply to: "Ketorolac Following Mastectomy: Is There an Increased Risk of Reoperation?― Annals of Surgical Oncology, 2021, 28, 777-778.	1.5	3
5	Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2021, 28, 5507-5512.	1.5	4
6	ASO Visual Abstract: Post-Discharge Non-Steroidal Anti-Inflammatory Drugs Are Not Associated with Risk of Hematoma After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2021, 28, 635-636.	1.5	0
7	Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema. Biology, 2021, 10, 934.	2.8	30
8	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event. JAMA Oncology, 2021, 7, 1851.	7.1	61
9	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Annals of Surgical Oncology, 2020, 27, 1617-1624.	1.5	20
10	Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. Annals of Surgical Oncology, 2020, 27, 4650-4661.	1.5	13
11	Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. Breast Cancer Research and Treatment, 2020, 184, 873-880.	2.5	8
12	Changing the Default: A Prospective Study of Reducing Discharge Opioid Prescription after Lumpectomy and Sentinel Node Biopsy. Annals of Surgical Oncology, 2020, 27, 4637-4642.	1.5	14
13	Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18 months of diagnosis. BMC Cancer, 2020, 20, 432.	2.6	7
14	Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era. Current Breast Cancer Reports, 2020, 12, 98-106.	1.0	0
15	Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. Annals of Surgical Oncology, 2019, 26, 3282-3288.	1.5	19
16	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. Annals of Surgical Oncology, 2019, 26, 4264-4271.	1.5	19
17	ASO Author Reflections: Does Genomic Testing of DCIS Provide Added Value? And Is It Worth the Cost?. Annals of Surgical Oncology, 2019, 26, 702-703.	1.5	0
18	ASO Author Reflections: Advising a Woman with Ductal Carcinoma In Situ Regarding Various Treatment Options—A Complex Decision. Annals of Surgical Oncology, 2019, 26, 4272-4273.	1.5	0

#	Article	IF	CITATIONS
19	Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. Annals of Surgical Oncology, 2019, 26, 4317-4325.	1.5	6
20	Ductal Carcinoma In Situ of the Breast. Advances in Surgery, 2019, 53, 21-35.	1.3	3
21	Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2019, 26, 2136-2143.	1.5	30
22	Acupuncture for breast cancer-related lymphedema: a randomized controlled trial. Breast Cancer Research and Treatment, 2018, 170, 77-87.	2.5	27
23	Trajectories of quality of life following breast cancer diagnosis. Breast Cancer Research and Treatment, 2018, 169, 163-173.	2.5	28
24	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer, 2018, 124, 46-54.	4.1	37
25	Surgical Treatment of Ductal CarcinomaÂln Situ. , 2018, , 171-192.		0
26	Controversies in the Treatment of Ductal Carcinoma in Situ. Annual Review of Medicine, 2017, 68, 197-211.	12.2	66
27	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Annals of Surgical Oncology, 2017, 24, 375-397.	1.5	61
28	Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Annals of Surgical Oncology, 2017, 24, 3888-3895.	1.5	13
29	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. Journal of the American College of Surgeons, 2017, 225, 740-746.	0.5	77
30	Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+). Annals of Surgical Oncology, 2017, 24, 3141-3147.	1.5	22
31	Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. Annals of Surgical Oncology, 2017, 24, 2889-2897.	1.5	28
32	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial: A Reply. Annals of Surgical Oncology, 2017, 24, 568-569.	1.5	2
33	Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers. Annals of Surgery, 2017, 266, 457-462.	4.2	90
34	Fibroepithelial Lesions in the Breast of Adolescent Females: A Clinicopathological Study of 54 Cases. Breast Journal, 2017, 23, 182-192.	1.0	31
35	Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ. International Journal of Surgical Pathology, 2017, 25, 100-107.	0.8	31
36	Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Practical Radiation Oncology, 2016, 6, 287-295.	2.1	135

#	Article	IF	CITATIONS
37	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology, 2016, 23, 3467-3474.	1.5	232
38	Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2016, 23, 2816-2824.	1.5	38
39	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2016, 23, 3481-3486.	1.5	25
40	Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. Annals of Surgical Oncology, 2016, 23, 3487-3493.	1.5	66
41	Margins in DCIS: Does Residual Disease Provide an Answer?. Annals of Surgical Oncology, 2016, 23, 3423-3425.	1.5	3
42	Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2016, 34, 4040-4046.	1.6	211
43	Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2016, 23, 3801-3810.	1.5	176
44	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. Annals of Surgical Oncology, 2016, 23, 4253-4261.	1.5	40
45	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology, 2016, 2, 397.	7.1	7
46	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. Annals of Surgical Oncology, 2016, 23, 257-264.	1.5	121
47	Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. Annals of Surgery, 2015, 262, 623-631.	4.2	94
48	Reexcision — The Other Breast Cancer Epidemic. New England Journal of Medicine, 2015, 373, 568-569.	27.0	33
49	Trajectories of Posttraumatic Growth and Associated Characteristics in Women with Breast Cancer. Annals of Behavioral Medicine, 2015, 49, 650-659.	2.9	65
50	Trajectories of Depressive Symptoms Following Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1789-1795.	2.5	45
51	Use of Axillary Staging in the Management of Ductal Carcinoma In Situ. JAMA Oncology, 2015, 1, 332.	7.1	3
52	Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Annals of Surgical Oncology, 2015, 22, 3273-3281.	1.5	46
53	Long-term rates of ipsilateral breast tumor recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy Journal of Clinical Oncology, 2015, 33, 560-560.	1.6	0
54	Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years Journal of Clinical Oncology, 2015, 33, 32-32.	1.6	1

#	Article	IF	CITATIONS
55	Extent of Microinvasion in Ductal Carcinoma In Situ is not Associated with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2014, 21, 3330-3335.	1.5	37
56	The Impact of Postmastectomy Radiotherapy on Two-Stage Implant Breast Reconstruction. Plastic and Reconstructive Surgery, 2014, 134, 588-595.	1.4	172
57	Local Relapse After Breast-Conserving Therapy for Ductal Carcinoma In Situ. Cancer Journal (Sudbury,) Tj ETQq1	1 0.78431 2.0	4 rgBT /Overi
58	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. Annals of Surgical Oncology, 2014, 21, 1552-1560.	1.5	50
59	Impact of Margin Assessment Method on Positive Margin Rate and Total Volume Excised. Annals of Surgical Oncology, 2014, 21, 86-92.	1.5	31
60	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. Annals of Surgical Oncology, 2014, 21, 22-27.	1.5	99
61	Use of Established Nomograms to Predict Non-Sentinel Lymph Node Metastasis. Current Breast Cancer Reports, 2014, 6, 24-31.	1.0	2
62	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. Journal of the National Cancer Institute, 2014, 106, .	6.3	73
63	Commentary on the Canadian National Breast Screening Study. Annals of Surgical Oncology, 2014, 21, 4397-4398.	1.5	0
64	Preoperative Breast MRI for Early-Stage Breast Cancer: Effect on Surgical and Long-Term Outcomes. American Journal of Roentgenology, 2014, 202, 1376-1382.	2.2	94
65	Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience. Annals of Surgical Oncology, 2013, 20, 4121-4127.	1.5	90
66	Age-related longitudinal changes in depressive symptoms following breast cancer diagnosis and treatment. Breast Cancer Research and Treatment, 2013, 139, 199-206.	2.5	69
67	Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?. Annals of Surgical Oncology, 2013, 20, 1302-1310.	1.5	7
68	Acupuncture in the treatment of upperâ \in imb lymphedema. Cancer, 2013, 119, 2455-2461.	4.1	64
69	A Comparison of Breast Surgeon and Nomogram-Generated Risk Predictions of Sentinel and Non-Sentinel Node Metastases. Journal of Cancer Therapy, 2013, 04, 1-6.	0.4	0
70	Breast Ductal Carcinoma In Situ. International Journal of Surgical Oncology, 2012, 2012, 1-2.	0.6	0
71	Validation of a Nomogram for Predicting Risk of Local Recurrence for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2012, 30, 3143-3144.	1.6	7
72	Memorial Sloan-Kettering Cancer Center: Two Decades of Experience with Ductal Carcinoma In Situ of the Breast. International Journal of Surgical Oncology, 2012, 2012, 1-8.	0.6	2

#	Article	IF	CITATIONS
73	Explaining age-related differences in depression following breast cancer diagnosis and treatment. Breast Cancer Research and Treatment, 2012, 136, 581-591.	2.5	55
74	Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified?. Annals of Surgical Oncology, 2012, 19, 3416-3421.	1.5	42
75	Papilloma Diagnosed at MRI-Guided Vacuum-Assisted Breast Biopsy: Is Surgical Excision Still Warranted?. American Journal of Roentgenology, 2012, 199, W512-W519.	2.2	27
76	Longâ€ŧerm outcomes in breast cancer patients undergoing immediate 2â€stage expander/implant reconstruction and postmastectomy radiation. Cancer, 2012, 118, 2552-2559.	4.1	113
77	Is There a Low-Grade Precursor Pathway in Breast Cancer?. Annals of Surgical Oncology, 2012, 19, 1115-1121.	1.5	20
78	Are Nomograms for the Prediction of Non-Sentinel Lymph Node Status Obsolete?. Breast Diseases, 2011, 22, 15-17.	0.0	0
79	Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma in Situ. Annals of Surgery, 2011, 253, 1233-1234.	4.2	Ο
80	Intracystic Papillary Carcinoma of the Breast. American Journal of Surgical Pathology, 2011, 35, 1-14.	3.7	118
81	The effect of age in the outcome and treatment of older women with ductal carcinoma in situ. Breast, 2011, 20, 71-77.	2.2	13
82	Morbidity of Sentinel Node Biopsy: Relationship Between Number of Excised Lymph Nodes and Patient Perceptions of Lymphedema. Annals of Surgical Oncology, 2011, 18, 2866-2872.	1.5	48
83	A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men. Breast Cancer Research and Treatment, 2011, 130, 301-306.	2.5	10
84	A Safety and Efficacy Pilot Study of Acupuncture for the Treatment of Chronic Lymphoedema. Acupuncture in Medicine, 2011, 29, 170-172.	1.0	38
85	Reply to U.K. Ballehaninna et al. Journal of Clinical Oncology, 2011, 29, e99-e99.	1.6	Ο
86	Reply to C. Mazouni et al. Journal of Clinical Oncology, 2011, 29, e45-e46.	1.6	2
87	Abstract 3139: Can PI3K/AKT pathway mutations predict for type of recurrence after conservative treatment for DCIS. , 2011, , .		0
88	The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. Annals of Surgery, 2010, 251, 583-591.	4.2	40
89	Predictors of Completion Axillary Lymph Node Dissection in Patients With Immunohistochemical Metastases to the Sentinel Lymph Node in Breast Cancer. Annals of Surgical Oncology, 2010, 17, 1063-1068.	1.5	14
90	Tissue Expander Breast Reconstruction is Not Associated with an Increased Risk of Lymphedema. Annals of Surgical Oncology, 2010, 17, 2926-2932.	1.5	25

#	Article	IF	CITATIONS
91	Minimal Disease in the Sentinel Lymph Node: How to Best Measure Sentinel Node Micrometastases to Predict Risk of Additional Non-Sentinel Lymph Node Disease. Annals of Surgical Oncology, 2010, 17, 2909-2919.	1.5	21
92	Morbidity of Sentinel Node Biopsy in Breast Cancer: The Relationship Between the Number of Excised Lymph Nodes and Lymphedema. Annals of Surgical Oncology, 2010, 17, 3278-3286.	1.5	76
93	Stage IV breast cancer in the era of targeted therapy. Cancer, 2010, 116, 1226-1233.	4.1	165
94	Incidence and time course of bleeding after longâ€ŧerm amenorrhea after breast cancer treatment. Cancer, 2010, 116, 3102-3111.	4.1	127
95	Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2010, 28, 3762-3769.	1.6	283
96	Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. Radiotherapy and Oncology, 2010, 94, 319-323.	0.6	49
97	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breastâ€conserving therapy. Cancer, 2009, 115, 1203-1214.	4.1	19
98	Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram. Annals of Surgical Oncology, 2009, 16, 1128-1135.	1.5	60
99	Mastectomy With Immediate Expander-Implant Reconstruction, Adjuvant Chemotherapy, and Radiation for Stage II–III Breast Cancer: Treatment Intervals and Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2008, 70, 43-50.	0.8	51
100	Desmoid Tumors (Fibromatoses) of the Breast: A 25-Year Experience. Annals of Surgical Oncology, 2008, 15, 274-280.	1.5	104
101	Predicting Nonsentinel Node Metastases in Sentinel Node-Positive Breast Cancer: What Have We Learned, Can We Do Better, and Do We Need To?. Annals of Surgical Oncology, 2008, 15, 2998-3002.	1.5	10
102	MRI Identifies Otherwise Occult Disease in Select Patients with Paget Disease of the Nipple. Journal of the American College of Surgeons, 2008, 206, 316-321.	0.5	77
103	Predictive Models: The Art and the Science. Breast Diseases, 2008, 19, 118-119.	0.0	0
104	Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Objective Measurements. Journal of Clinical Oncology, 2008, 26, 5213-5219.	1.6	530
105	Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Patient Perceptions and Precautionary Behaviors. Journal of Clinical Oncology, 2008, 26, 5220-5226.	1.6	187
106	Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation. Journal of Clinical Oncology, 2007, 25, 3670-3679.	1.6	283
107	A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram. Annals of Surgery, 2007, 245, 462-468.	4.2	126
108	Perpendicular Inked Versus Tangential Shaved Margins in Breast-Conserving Surgery: Does the Method Matter?. Journal of the American College of Surgeons, 2007, 204, 541-549.	0.5	47

#	Article	IF	CITATIONS
109	Can Surgical Oncologists Reliably Predict the Likelihood for Non-SLN Metastases in Breast Cancer Patients?. Annals of Surgical Oncology, 2007, 14, 615-620.	1.5	19
110	Eighteen Sensations After Breast Cancer Surgery: A 5-Year Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Annals of Surgical Oncology, 2007, 14, 1653-1661.	1.5	50
111	Validating a Predictive Model for Presence of Additional Disease in the Non–Sentinel Lymph Nodes of a Woman with Sentinel Node Positive Breast Cancer. Annals of Surgical Oncology, 2007, 14, 2177-2178.	1.5	13
112	Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit. Annals of Surgical Oncology, 2007, 14, 2911-2917.	1.5	66
113	Clinicopathologic Features and Long-Term Outcomes of 293 Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2007, 14, 2961-2970.	1.5	203
114	A 14-Year Retrospective Review of Angiosarcoma. Cancer Journal (Sudbury, Mass), 2005, 11, 241-247.	2.0	350
115	Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer. Annals of Surgical Oncology, 2005, 12, 1045-1053.	1.5	121
116	Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. Annals of Surgical Oncology, 2005, 12, 654-659.	1.5	211
117	Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?. Annals of Surgical Oncology, 2005, 12, 1066-1072.	1.5	108
118	Mri-Guided Needle Localization. , 2005, , 23-27.		0
119	Total Mastectomy. , 2005, , 79-91.		Ο
120	Eighteen Sensations After Breast Cancer Surgery: A Two-Year Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Oncology Nursing Forum, 2004, 31, 691-698.	1.2	36
121	Minimally invasive breast surgery. Journal of the American College of Surgeons, 2004, 199, 961-975.	0.5	14
122	A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. Annals of Surgical Oncology, 2004, 11, 535-541.	1.5	67
123	A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer, 2004, 101, 2509-2515.	4.1	42
124	A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2003, 10, 1140-1151.	1.5	747
125	The Accuracy of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Invasive Breast Cancers. Journal of the American College of Surgeons, 2003, 197, 529-535.	0.5	127
126	MR Imaging Findings in the Contralateral Breast of Women with Recently Diagnosed Breast Cancer. American Journal of Roentgenology, 2003, 180, 333-341.	2.2	287

#	Article	IF	CITATIONS
127	Fast MRI-Guided Vacuum-Assisted Breast Biopsy:Initial Experience. American Journal of Roentgenology, 2003, 181, 1283-1293.	2.2	134
128	Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 199-206.	4.9	22
129	One Operation After Percutaneous Diagnosis of Nonpalpable Breast Cancer. American Journal of Roentgenology, 2002, 178, 673-679.	2.2	41
130	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	2.2	94
131	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	2.2	196
132	Eighteen Sensations After Breast Cancer Surgery: A Comparison of Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection. Oncology Nursing Forum, 2002, 29, 651-659.	1.2	43
133	Breast imaging: a breast surgeon's perspective. Radiologic Clinics of North America, 2002, 40, 517-520.	1.8	0
134	Reoperative Sentinel Lymph Node Biopsy. Journal of the American College of Surgeons, 2002, 195, 167-172.	0.5	120
135	Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Annals of Surgical Oncology, 2002, 9, 654-662.	1.5	122
136	Sentinel Lymph Node Drainage in Multicentric Breast Cancers. Breast Journal, 2002, 8, 356-361.	1.0	43
137	Sensory Morbidity After Sentinel Lymph Node Biopsy and Axillary Dissection: A Prospective Study of 233 Women. Annals of Surgical Oncology, 2002, 9, 654-662.	1.5	12
138	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	1.5	90
139	Is It Really Duct Carcinoma In Situ?. Annals of Surgical Oncology, 2001, 8, 617-617.	1.5	23
140	Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. Breast Cancer Research and Treatment, 2001, 66, 239-248.	2.5	189
141	Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma. Breast Cancer Research and Treatment, 2001, 65, 225-232.	2.5	23
142	Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas*. Breast Cancer Research and Treatment, 2001, 69, 115-122.	2.5	33
143	Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. Cancer Genetics and Cytogenetics, 2001, 125, 131-138.	1.0	18
144	Comprehensive review of the management of internal mammary lymph node metastases in breast cancer 1 1No competing interests declared Journal of the American College of Surgeons, 2001, 193, 547-555.	0.5	84

#	Article	IF	CITATIONS
145	Bracketing Wires for Preoperative Breast Needle Localization. American Journal of Roentgenology, 2001, 177, 565-572.	2.2	89
146	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	1.5	6
147	In microdissected ductal carcinoma in situ, HER-2/neu amplification, but notp53 mutation, is associated with high nuclear grade and comedo histology. Cancer, 2000, 89, 2153-2160.	4.1	37
148	Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer11No competing interests declared Journal of the American College of Surgeons, 2000, 191, 593-599.	0.5	72
149	Chest wall resection for locally recurrent breast cancer: Is it worthwhile?. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 420-428.	0.8	61
150	Magnetic Resonance Imaging Facilitates Breast Conservation for Occult Breast Cancer. Annals of Surgical Oncology, 2000, 7, 411-415.	1.5	162
151	Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion?. Annals of Surgical Oncology, 2000, 7, 636-642.	1.5	304
152	Evaluation of Pectoralis Major Muscle in Patients with Posterior Breast Tumors on Breast MR Images: Early Experience. Radiology, 2000, 214, 67-72.	7.3	105
153	Are breast cancer patients at increased risk for colorectal adenomas and cancer: Effect of family history and age. Gastroenterology, 2000, 118, A44.	1.3	0
154	Issues of Regret in Women With Contralateral Prophylactic Mastectomies. Annals of Surgical Oncology, 1999, 6, 546-552.	1.5	162
155	Six-Year Follow-Up of Patients With Microinvasive, T1a, and T1b Breast Carcinoma. Annals of Surgical Oncology, 1999, 6, 591-598.	1.5	34
156	Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery. , 1999, 86, 1757-1767.		114
157	Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene, 1998, 16, 2723-2727.	5.9	43
158	Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. , 1998, 82, 1874-1880.		94
159	Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. Annals of Surgical Oncology, 1998, 5, 757-763.	1.5	25
160	Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Annals of Surgical Oncology, 1998, 5, 23-27.	1.5	56
161	Patient regrets after bilateral prophylactic mastectomy. Annals of Surgical Oncology, 1998, 5, 603-606.	1.5	107
162	Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. Cancer, 1998, 82, 1874-1880.	4.1	12

#	Article	IF	CITATIONS
163	Microsatellite instability in breast cancer. Annals of Surgical Oncology, 1997, 4, 310-315.	1.5	17
164	Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens. Annals of Surgical Oncology, 1997, 4, 416-420.	1.5	8
165	Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer. Annals of Behavioral Medicine, 1997, 19, 362-369.	2.9	131
166	Ductal carcinoma in situ of the breast: Progress and controversy. Current Problems in Surgery, 1996, 33, 555-600.	1.1	18
167	The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. Journal of Clinical Immunology, 1994, 14, 120-133.	3.8	28
168	Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. European Journal of Immunology, 1993, 23, 1889-1894.	2.9	148
169	Comparison of Peripheral Blood Leukocyte Kinetics After Live Escherichia coli, Endotoxin, or Interleukin-1 α Administration Studies Using a Novel Interleukin-1 Receptor Antagonist. Annals of Surgery, 1993, 218, 79-90.	4.2	30